Quality of Life in Spanish advanced non-small-cell lung cancer patients: determinants of global QL and survival analyses

Abstract

PurposeThis paper studies the Quality of Life (QL) of Spanish advanced non-small-cell lung cancer (NSCLC) patients receiving platinum-doublet chemotherapy, compares our results with those from studies from other cultural areas, and identifies factors associated with global QL and survival prognostic variables.MethodsEORTC QLQ-C30 and QLQ-LC13 questionnaires were completed three times by 39 patients along treatment and follow-up. Univariate and multivariate logistic regression analyses were performed to study global QL determinants (≤50 points considered low global-QL score). Analyses of prognostic variables for death were performed (Cox proportional hazards models).ResultsQL mean scores in the whole sample were moderately high, with limitations (>30) in physical, role, social functioning, emotional areas, fatigue, pain, neuropathy and global QL. Differences with studies from other cultural areas were mainly found in the lower score for dyspnoea (≥15 points). There were no significant differences in QL scores between the first and second assessments. In six areas, the third assessment was lower than the first and second: fatigue, hair loss (>20 points); physical, social functioning, neuropathy (10–20 points); emotional functioning (5–10 points). The best model to explain the chances of low QL includes, as explanatory variables, high emotional functioning as protective factor and fatigue as risk factor (R2 = 0.70). Eight QL areas (four pain-related) and performance status showed a statistically significant association with survival.ConclusionPatients adapted well to their disease and treatments. Platinum-doublet can be administered in advanced NSCLC patients. Our QL data are in line with those from other cultural areas.

<em>nab</em>-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy

“…Another study assessed QoL changes in patients with advanced NSCLC (N = 39) and found significant declines from baseline in physical and social functioning, among other QoL areas, during treatment with platinum-doublet chemotherapy. 29 In the current study evaluating nab -paclitaxel plus carboplatin treatment, some health status issues (individual EQ-5D-5L dimensions of mobility, anxiety/depression, usual activities, pain/discomfort, and self-care) were maintained or improved in the majority of patients, with ≈30% reporting complete resolution from baseline at least once during treatment.…”

The effect of coping strategy on quality of life in patients with NSCLC

“…The number of cancer patients is increasing, but the reduction in mortality due to cancer is still insufficient despite high expenditure on research on new cancer therapies. 7 , 9 We believe that shedding more light on the relationship between coping strategies and quality of life will contribute to improvements in the heath of patients with neoplastic diseases. In the current literature, coping styles in cancer patients have not been studied sufficiently, especially among those with lung cancer who may have different coping strategies due to specific stressors (eg, dyspnea) and the stigma associated with smoked tobacco.…”

Inflammation‐ and angiogenesis‐related biomarkers are correlated with cancer‐related fatigue in colorectal cancer patients: Results from the ColoCare Study

“…The mean fatigue scores differed slightly between different time points (35.3 ± 29.4 vs. 40.7 ± 28.8 vs. 33.5 ± 27.6 points, p = 0.05 respectively). Over 60% of the patients reported fatigue scores of > 30 at each study time point which has been shown to moderately limit the patient's quality of life (Arraras et al, 2016). N = 236 serum samples were measured.…”